SCHRODER INVESTMENT MANAGEMENT GROUP
Position in AXSM — Axsome Therapeutics, Inc.
CIK 1086619
London, X0
Position in AXSM
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$4,027,746
+$115,105 QoQ
Shares Held
23,830
-36.4% QoQ
Ownership
0.045%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AXSM Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SCHRODER INVESTMENT MANAGEMENT GROUP holds $692,439,062 across 60 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TECH |
BIO-TECHNE Corp
|
1,410,943 | $99,683,122 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
169,270 | $84,081,485 | |
| 3 | EXEL |
Exelixis, Inc.
|
669,005 | $36,400,560 | |
| 4 | INSM |
INSMED Inc
|
298,372 | $31,812,422 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
95,194 | $28,656,248 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
51,630 | $27,722,728 | |
| 7 | VERA |
Vera Therapeutics, Inc.
|
510,787 | $21,917,869 | |
| 8 | TVTX |
Travere Therapeutics, Inc.
|
379,611 | $21,565,700 |
All Filings in AXSM
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,027,746 | 23,830 | Shares | Sole | 2026-05-14 | |
| 2025-06-30 | $3,912,641 | 37,481 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $2,815,681 | 24,142 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $2,042,654 | 24,142 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $5,239,421 | 58,300 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $4,693,150 | 58,300 | Shares | Sole | 2024-08-12 | |
| 2024-03-31 | $4,652,340 | 58,300 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $4,640,097 | 58,300 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||